Lantheus Holdings, Inc. (LNTH) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Lantheus Holdings, Inc. (LNTH) stock forecast summary
Our AI ranks Lantheus Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Lantheus Holdings, Inc. is a mid-cap company with a market capitalization of $6.53B. It ranks number 2 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for LNTH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LNTH included.
Follow LNTH freeLNTH price chart and AI forecast
How LNTH ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Lantheus Holdings, Inc. (LNTH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | LNTH | Rank |
|---|---|---|
| Market Cap | $6.53B | 2/15 |
| P/E Ratio | 23.71x | – |
| P/B Ratio | 4.98x | 3/11 |
| EPS | $4.18 | – |
| Book Value/Share | $20.10 | – |
| Revenue/Share | $23.84 | – |
Profitability & Margins
| Metric | LNTH | Rank |
|---|---|---|
| ROE | 21.0% | 2/11 |
| ROA | 11.4% | 2/13 |
| ROIC | 14.5% | 2/11 |
| Gross Margin | 60.1% | 3/9 |
| Operating Margin | 19.4% | 2/14 |
| Net Margin | 17.7% | 2/11 |
| EBT Margin | 23.3% | 2/14 |
| Tax Rate | 24.1% | – |
Financial Health
| Metric | LNTH | Rank |
|---|---|---|
| Current Ratio | 3.06x | 8/15 |
| Quick Ratio | 2.89x | 3/9 |
| D/E Ratio | 0.84x | 4/12 |
| Financial Leverage | 1.84x | 4/12 |
| Interest Coverage | 5.1x | 6/14 |
| Working Capital | $691M | 1/15 |
Cash Flow
| Metric | LNTH | Rank |
|---|---|---|
| Operating Cash Flow | $413M | 2/16 |
| OCF Growth YoY | -21.7% | 4/5 |
Operational Efficiency
| Metric | LNTH | Rank |
|---|---|---|
| Asset Turnover | 0.64x | 4/12 |
| Receivables Turnover | 4.4x | 10/11 |
| Inventory Turnover | 10.8x | 2/9 |
| Fixed Assets Turnover | 10.2x | 1/12 |
| Days Sales Outstanding | 83 days | 2/11 |
| Days Inventory | 34 days | 8/9 |
| Payables Period | 28 days | 7/9 |
| Cash Conversion Cycle | 88 days | 6/8 |
Income Statement
| Metric | LNTH | Rank |
|---|---|---|
| Total Revenue | $1.56B | 3/12 |
| Operating Income | $302M | 2/15 |
| Net Income | $275M | 2/13 |
| R&D Expense | $173M | 5/16 |
| SG&A Expense | $612M | 3/12 |
| Cost of Goods Sold | $620M | 3/10 |
Dividend & Shareholder Information
| Metric | LNTH | Rank |
|---|---|---|
| Shares Outstanding | 65M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.03B | 42.5% of assets |
| Cash & Short-term Investments | $593M | 24.6% of assets |
| Accounts Receivable | $353M | 14.6% of assets |
| Inventory | $58M | 2.4% of assets |
| Total Liabilities | $1.10B | 45.7% of assets |
| Short-term Debt | $288M | 11.9% of assets |
LNTH quarterly financials and insider trading
Lantheus Holdings, Inc. (LNTH) industry peers
Companies classified under the same SEC industry code as Lantheus Holdings, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where LNTH sits on the market map
Lantheus Holdings, Inc. (LNTH) stock news
Loading...
Lantheus Holdings, Inc. (LNTH) stock forecast FAQ
What is the Lantheus Holdings, Inc. (LNTH) stock forecast?
Our AI ranks Lantheus Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Lantheus Holdings, Inc. stock predictions?
A per-ticker accuracy statistic for LNTH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lantheus Holdings, Inc. forecasts updated?
Lantheus Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Lantheus Holdings, Inc.'s industry peers?
17 issuers in our coverage, LNTH included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.